ARIA: The effects of aliskiren on albuminuria in non-diabetic nephropathy patients treated with ramipril and volume intervention.
Recruiting
- Conditions
- iet diabetische nefropathie/Non-diabetic nefropathy
- Registration Number
- NL-OMON21705
- Lead Sponsor
- MCG, Novartis
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
1. Male and female outpatients at least 18 years old;
2. Non-diabetic renal disease as established by history, urine analysis, serum biochemistry tests and/or renal biopsy with residual albuminuria by UAER of >300 mg/24 hrs from 24 hour urine collection during conventional RAAS-blockade of at least 8 weeks of ACEinhibition or ARB treatment at the maximum recommended dose;
Exclusion Criteria
1. Previously treated (within 3 months of screening) with aliskiren or a combination of
aliskiren and ramipril;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albuminuria.
- Secondary Outcome Measures
Name Time Method 1. RAAS-biomarkers;<br /><br>2. Renal function (GFR/hemodynamic measurements);<br /><br>3. Blood pressure.